41/100US=90 / Biol/Mol
Wislez M, Kurie JM. EGFR signaling networks: the intersection of EGFR and the Ras signaling pathway. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 89-95. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

CANCER DE PULMAO; RAS; LIGANTES

42/100US=90 / Biol/Mol
Domin J. EGFR signaling networks: phosphoinositide 3-kanase enzymes as downstrem targets of the EGF receptor. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 97-117. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

AKT; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR; QUINASE; FOSFATIDILINOSITOL; TRANSDUCAO DE SINAL; CELULA; CANCER; MITOGENESE; APOPTOSE; ENDOCITOSE

43/100US=90 / Biol/Mol
Pritchard JE, Jablonski AB, Parsons SJ. EGFR signaling networks: convergence of EGF receptor and Src family signaling networks in cancer. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 119-37. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

RECEPTOR DE EGF; EGFR; C-SRC

44/100US=90 / Biol/Mol
Gavard J, Gutkind JS. EGFR signaling networks: a molecular crosstalk between e-cadlherin and EGFR signaling networks. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 139-54. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

EGFR; JUNCOES CELULARES; ADESAO CELULAR; CADERINA; CATENINA MIGRACAO; ACTINA

45/100US=90 / Biol/Mol
Becker MA, Yee D. EGFR signaling networks: crosstalk between insulin-like growth factor (IGF) and epidermal growth factor (EGF) receptors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 155-68. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

EGFR; IGF-IR; CANCER; MSPK; PI3K; CROSSTALK

46/100US=90 / Biol/Mol
Carraway KL, Yen L, Ingalla E, Sweeney C. EGFR signaling networks: negative regulation of signaling by the EGFR family. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 169-86. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

RECEPTOR EGF; CANCER DE MAMA; ERBB2; REGULADOR NEGATIVO; UBIQUITINA LIGASE E3; CAMUNDONGOS TRANSGENICOS

47/100US=90 / Biol/Mol
Lao HJ, Carpenter G. EGFR signaling networks: nuclear ErbB receptors: pathways and functions. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 187-97. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

ERBB; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; NUCLEO; SINALIZAR; TRANSDUCAO

48/100US=90 / Biol/Mol
Blagoev B, Kratchmarova I, Olsen JV, Mann M. EGFR signaling networks: temporal dynamics of EGF receptor signaling by quantitative proteomics. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 199-207. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; NUCLEO; SINALIZAR; TRANSDUCAO

49/100US=90 / Biol/Mol
Johnson CG, McIntyre E, Gullick W. EGFR signaling networks: computational and mathematical modeling of the EGF receptor system. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 209-18. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

EGF RECEPTOR; MODELOS DE MATEMATICA; MODELOS DE PROGRAMAS

50/100US=90 / Biol/Mol
Normanno N, Bianco C, De Luca A, Strizzi L, Gallo M, Mancino M, Salomon DS. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: expression and prognostic significance of the EGFR in solid tumors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 221-34. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

EGFR; ERBB2; ERBB3; ERBB4; EGF-COMO FATOR DE CRESCIMENTO; CANCER; PROGNOSTICO

51/100US=90 / Biol/Mol
Bennett HL, Brummer T, Timpson P, Patterson KI, Daly RJ. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: signaling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 235-55. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

SRC; RAS; RAF; ERK; PI3-QUINASE; PTEN; EGFR INIBIDORES; LOOPS DE FEEDBACK; C-CBL; ENDOCITOSE

52/100US=90 / Biol/Mol
Box C, Peak J, Rogers S, Eccles S. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: EGFR signaling in invasion, angiogenesis and metastasis. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 257-76. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

INVASAO; ADESAO; MOTILIDADE; PROTEOLISE; ANGIOGENESE; LINFANGIOGENESE; METASTASE

53/100US=90 / Biol/Mol
Wikstrand CJ, Bigner DD. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: constitutive activation of truncated EGF receptors in glioblastoma. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 277-92. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

AMPLIFICACAO DO GENE; IMUNOTERAPIA; MUTACAO; NEOPLASIAS DO SISTEMA NERVOSO; TRANSDUCAO DE SINAL

54/100US=90 / Biol/Mol
Eberhard DA. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: EGFR mutations, other molecular alterations related to sensitivity to EGFR-targeted therapies in non-small cell lung cancer. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 293-336. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INIBIDORES DE QUINASE DE TIROSINA; DIAGNOSTICOS MOLECULARES; MUTACOES; HIBRIDACAO IN SITU FLUORESCENTE; IMUNOHISTOQUIMICA; CANCER DE PULMAO

55/100US=90 / Biol/Mol
Dannenberg AJ, Subbaramaiah K. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: crosstalk between COX-2 and EGFR: apontential therapeutic opportunity. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 337-51. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

CICLOOXIGENASE-2; PROSTAGLANDINAS; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; CROSSTALK; CANCER

56/100US=90 / Biol/Mol
Thomson S, Haley JD, Yauch R. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: cellular sensitivity to EGF receptor inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 353-68. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

EGFR; HER2; HER3; ERLOTINIB; A TRANSICAO EPITELIAL MESENQUIMAL; INIBIDORES DE QUINASE DE TIROSINA

57/100US=90 / Biol/Mol
Buck E, Eyzaguirre A, Iwata KK. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: utilizing combination of molecular targeted agents to sensitize tumor cells to EGFR inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 369-82. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

EMT; TRANSICAO EPITELIAL MESENQUIMAL; ERLOTINIB; EGFR; IGF-1R; ER; HER3; MTOR; HDAC; SRC; COX-2

58/100US=77-J / Câncer
Formiga MNC. Terapias alvos específicos. In: Lopes A, Chammas R, Iyeyasu H. Oncologia para a graduação. 3ª ed. São Paulo: Lemar, 2013. p. 235-7. ISBN 8-5866523-7-0.

CANCER. TERAPIA; INIBIDORES DE ANGIOGENESE; INIBIDORES DE MTOR; INIBIDORES DE EGFR; AGENTES ANTI-SENSE; RNA DE INTERFERENCIA (RNAI)

59/100US=92 / Biol/Mol
Deininger M. Established cancer therapies: tyrosine kinase inhibitors. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 477-508. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9.

TERAPIA-ALVO; BCR-ABL; FLT3; EGFR; TYROSISE INIBITORS QUINASE; IMATINIB; GEFITINIB; ERLOTINIB; CANCER; LEUCEMIA

60/100US=2 / Mama
Ciardiello F, Troiani T, Tortora G. Tissue predictive biomakers: the epidermal growth factor receptor pathway as a selective molecular-targeted treatment in human breast cancer. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 177-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCAORES PREDITIVOS; FATOR DE CRESCIMENTO EPIDERMICO; VIA RECEPTOR; CANCER DE MAMA; EGF; EGFR

Primeira | Anterior | Próxima | Última